[subscription] AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, received a $315 million Series D led by Ally Bridge Group and Alpha Wave.. AdvanCell. Fwd: Stripe and Advent's lowball bid

Aethlon Medical, Inc. (AEMD): Two of three cohorts in our Hemopurifier oncology clinical trial have been completed, with no safety concerns reported by the Data Safety Monitoring Board | Aethlon Medical, Inc. - AnnualReports.com: Aethlon Medical (NASDAQ: AEMD) is <strong>focused on addressing unmet needs in global health and biodefense</strong>. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. | Company Information :: Aethlon Medical, Inc. (AEMD): Aethlon Medical <strong>develops immunotherapeutic technologies to combat can